U.S. Food and Drug Administration (FDA) approved a new delivery device for Neulasta (pegfilgrastim) for non-Hodgkin patients who do not need to return to the clinic the day after chemotherapy. More >
Welcome to Focus on ALCL
The FocusOnALCL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by anaplastic large cell lymphoma.
We invite you to browse the website to learn more about ALCL.
Getting the Facts
Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma (NHL), but the second or third most common subtype of T-cell lymphoma. There are three types of ALCL and altogether they comprise about 3 percent of all NHLs in adults and between 10 percent and 30 percent of all NHLs in children. It can present either systemically or in the skin.
Research into anaplastic large cell lymphoma has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.